Human induced pluripotent stem cells and neurodegenerative disease
Jung YW, Hysolli E, Kim KY, Tanaka Y, Park IH. Human induced pluripotent stem cells and neurodegenerative disease. Current Opinion In Neurology 2012, 25: 125-130. PMID: 22357218, PMCID: PMC3786112, DOI: 10.1097/wco.0b013e3283518226.Peer-Reviewed Original ResearchConceptsNeurodegenerative diseasesReplacement therapyCell replacement therapyParkinson's diseasePositive therapeutic effectDisease modelsParkinson's disease modelAmyotrophic lateral sclerosisNeuron-specific transcription factorSpinal muscular atrophyStem cellsDrug screeningDopaminergic neuronsIntermediate cell typeTherapeutic effectEffective treatmentLateral sclerosisDisease-specific iPSCsMuscular atrophyAlzheimer's diseaseNeurodegenerative disordersCellular therapyDiseaseTherapyHuman induced pluripotent stem cellsOvercoming reprogramming resistance of Fanconi anemia cells
Müller LU, Milsom MD, Harris CE, Vyas R, Brumme KM, Parmar K, Moreau LA, Schambach A, Park IH, London WB, Strait K, Schlaeger T, DeVine AL, Grassman E, D'Andrea A, Daley GQ, Williams DA. Overcoming reprogramming resistance of Fanconi anemia cells. Blood 2012, 119: 5449-5457. PMID: 22371882, PMCID: PMC3369681, DOI: 10.1182/blood-2012-02-408674.Peer-Reviewed Original ResearchConceptsFA cellsFA pathwayFA DNA repair pathwayFanconi anemiaDNA double-strand breaksFanconi anemia cellsStem cellsDNA repair pathwaysDouble-strand breaksDisease-specific iPSCsPluripotent stem cellsFuture translational applicationsGenomic integrityHuman primary cellsHematopoietic stem cellsHematopoietic differentiationChromosomal instabilityMolecular characterizationGene correctionTransgenic expressionDNA damageGenetic correctionHematopoietic cellsPrimary cellsPathway